Loading ...

Stock Quote 1101

1101 Stock Price Today

1101 Price History

1101 Stock Price History

1101 History

Last Price 1101

Close Price 1101

Day Change 1101

After Hours Quote 1101

Open Price 1101

Day Range 1101

Year Range 1101

Projected Yield 1101

Market Cap 1101

Stock Volume 1101

Average Volume 1101

Forward Price 1101

PE for 1101

PB for 1101

PS for 1101

PCF for 1101

price earnings ratio 1101

price to book ratio 1101

price to sales ratio 1101

price to cash flow ratio 1101

Stock Quote Taiwan Cement Corp

Taiwan Cement Corp Stock Price today

Taiwan Cement Corp Price history

Taiwan Cement Corp Stock Price history

Taiwan Cement Corp history

Last Price Taiwan Cement Corp

Close Price Taiwan Cement Corp

Day Change Taiwan Cement Corp

After Hours Quote for Taiwan Cement Corp

Open Price Taiwan Cement Corp

Day Range Taiwan Cement Corp

Year Range Taiwan Cement Corp

Projected Yield Taiwan Cement Corp

Market Cap Taiwan Cement Corp

Stock Volume Taiwan Cement Corp

Average Volume Taiwan Cement Corp

Forward Price Taiwan Cement Corp

pe Taiwan Cement Corp

pb Taiwan Cement Corp

ps Taiwan Cement Corp

pcf Taiwan Cement Corp

price earnings ratio Taiwan Cement Corp

price to book ratio Taiwan Cement Corp

price to sales ratio Taiwan Cement Corp

price to cash flow ratio Taiwan Cement Corp

What Does This Company Do?
Taiwan Cement Corp is engaged in production and marketing of cement & cement products. Its products include Portland cement, high strength cement, oil well cement, & sludge treatment agents.
Sector
Basic Materials
Industry
Building Materials
Stock Type
Employees
10409
Stock Style
Large Core

Key Stats  1101 More...

Key Stats 1101

S&P 500 index data: S&P 500 Copyright ©

All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .

News  1101 - Taiwan Cement Corp More...

Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib (Imbruvica(R)) for Patients With Select B-Cell Malignancies
Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days

Analysis  1101 - Taiwan Cement Corp More...

Free Issue - Morningstar's Dividend Newsletter
More...

An investment is only as good as the cash it returns directly to your pockets. That's why Morningstar DividendInvestor's buy and sell recommendations are driven entirely by dividends. Our total-return strategy gives you carefully selected, picks that combine current income and income growth to generate large, reliable and growing cash returns. Click to try!

More reports 1101 - Taiwan Cement CorpMore...

Click above to view more mutual fund data and stats for 1101 - Taiwan Cement Corp.

  • Performance
  • Asset Allocation
  • Dividend and Capital Gains Distribution
  • News, Alerts and Opinions
  • Video reports
  • Management
  • Filings

Ownership   1101 More ...

Ownership 1101

Vanguard Emerging Mkts Stock Idx Inv
DFA Emerging Markets Value I
T. Rowe Price New Asia
Vanguard Total Intl Stock Index Inv
DFA Emerging Markets Core Equity I
Stock Price Quote: 1101 Taiwan Cement Corp - XTAI - Morningstar
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry

Previous: 9941 - Taiwan Acceptance Corp  |  Next: 8926 - Taiwan Cogeneration Corp